Published in J Immunol on July 15, 2007
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. Dig Dis Sci (2009) 0.84
Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice. PLoS One (2013) 0.84
A closer look at the role of urotensin II in the metabolic syndrome. Front Endocrinol (Lausanne) (2012) 0.84
Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by p38 MAPK and ERK activations. Heart Vessels (2012) 0.80
Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice. Oncol Lett (2012) 0.79
The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells. PLoS One (2015) 0.79
Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart. Br J Pharmacol (2012) 0.77
Increased susceptibility of melanin-concentrating hormone-deficient mice to infection with Salmonella enterica serovar Typhimurium. Infect Immun (2012) 0.77
IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure. Oncotarget (2016) 0.77
Desensitisation of native and recombinant human urotensin-II receptors. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.76
Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma. Oncogene (2015) 0.76
The Autophagy Machinery: A New Player in Chemotactic Cell Migration. Front Neurosci (2017) 0.75
Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis. Autophagy (2016) 0.75
Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2. Oncotarget (2016) 0.75
Urotensin 2 in Kawasaki disease pathogenesis. Pediatr Res (2017) 0.75
The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features. Front Endocrinol (Lausanne) (2017) 0.75
Rho kinases in cardiovascular physiology and pathophysiology. Circ Res (2006) 2.97
The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med (2010) 1.84
Enteric glia protect against Shigella flexneri invasion in intestinal epithelial cells: a role for S-nitrosoglutathione. Gut (2010) 1.73
Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res (2003) 1.68
Enteric GFAP expression and phosphorylation in Parkinson's disease. J Neurochem (2014) 1.51
RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem (2003) 1.35
Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. J Cell Sci (2004) 1.33
RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med (2009) 1.28
Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem (2006) 1.27
Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circ Res (2005) 1.24
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol (2005) 1.24
The role of Rho protein signaling in hypertension. Nat Rev Cardiol (2010) 1.23
The digestive neuronal-glial-epithelial unit: a new actor in gut health and disease. Nat Rev Gastroenterol Hepatol (2012) 1.22
Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology (2003) 1.21
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol (2006) 1.20
Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation (2003) 1.20
Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol (2002) 1.12
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol (2002) 1.07
Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation. Circ Res (2008) 1.05
Shear stress regulates endothelial microparticle release. Circ Res (2013) 1.05
RhoE Is required for keratinocyte differentiation and stratification. Mol Biol Cell (2008) 1.05
Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res (2006) 1.04
RhoA activation and interaction with Caveolin-1 are critical for pressure-induced myogenic tone in rat mesenteric resistance arteries. Cardiovasc Res (2006) 1.04
Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells. Am J Physiol Cell Physiol (2009) 1.03
Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res (2011) 1.03
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother (2002) 1.00
Small G proteins in the cardiovascular system: physiological and pathological aspects. Physiol Rev (2013) 0.97
WNK1 regulates vasoconstriction and blood pressure response to α 1-adrenergic stimulation in mice. Hypertension (2011) 0.95
Regulation of Rho proteins by phosphorylation in the cardiovascular system. Trends Cardiovasc Med (2006) 0.94
Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation (2010) 0.93
RhoA phosphorylation induces Rac1 release from guanine dissociation inhibitor alpha and stimulation of vascular smooth muscle cell migration. Mol Cell Biol (2010) 0.90
Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides (2004) 0.90
AMPK alpha 1-induced RhoA phosphorylation mediates vasoprotective effect of estradiol. Arterioscler Thromb Vasc Biol (2011) 0.90
Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer (2002) 0.89
Rho exchange factors in the cardiovascular system. Curr Opin Pharmacol (2008) 0.89
Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One (2011) 0.86
Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. J Immunol (2002) 0.86
Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. J Med Chem (2007) 0.86
The Rho protein exchange factor Vav3 regulates vascular smooth muscle cell proliferation and migration. Cardiovasc Res (2009) 0.86
RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol (2005) 0.86
PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol Immunother (2007) 0.85
Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res (2004) 0.85
Tumor-reactive CD4+ CD8αβ+ CD103+ αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. Int J Cancer (2010) 0.84
Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions. Int J Cancer (2009) 0.84
Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res (2003) 0.83
Regulation of Rho signaling pathways in interleukin-2-stimulated human T-lymphocytes. FASEB J (2005) 0.83
Drug-eluting stents in bifurcations: bench study of strut deformation and coating lesions. Circ Cardiovasc Interv (2010) 0.83
Structure-activity relationships of urotensin II and URP. Peptides (2007) 0.83
Identification of differentially expressed genes in human varicose veins: involvement of matrix gla protein in extracellular matrix remodeling. J Vasc Res (2007) 0.83
Role of Rho kinase signalling in healthy and varicose human saphenous veins. Br J Pharmacol (2002) 0.82
Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS One (2010) 0.82
Urotensin II and atherosclerosis. Peptides (2007) 0.81
HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation. PLoS One (2012) 0.81
Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem (2003) 0.80
RhoA guanine exchange factor expression profile in arteries: evidence for a Rho kinase-dependent negative feedback in angiotensin II-dependent hypertension. Am J Physiol Cell Physiol (2012) 0.80
Cardiac Protective Effects of Moringa oleifera Seeds in Spontaneous Hypertensive Rats. Am J Hypertens (2016) 0.79
Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. Small GTPases (2014) 0.79
Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Mol Biosyst (2006) 0.78
Electrografting of a biodegradable layer as a primer adhesion coating onto a metallic stent: in vitro and in vivo evaluations. J Mater Sci Mater Med (2013) 0.78
Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. J Med Chem (2006) 0.78
[Passive immunotherapy of melanoma]. Bull Cancer (2003) 0.77
Direct stenting limits sirolimus-eluting stent edge neointimal thickening. J Vasc Surg (2007) 0.76
Rho-kinase inhibitors: pharmacomodulations on the lead compound Y-32885. J Enzyme Inhib Med Chem (2002) 0.76